Media Resources
Living Cell Technologies is commited to providing up-to-the-minute information about our research, scientific results, clinical trials and productisation. Here you will find the latest media resources including an archive of previous material over the period of the company’s operation.
LCT Expands Diabetes Clinical Trial
June 5, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY) today announced that the positive preliminary data from its first clinical trial of Diabecell® for insulin dependent type 1 diabetes has encouraged the Company to expand the trial and proceed with testing higher doses.
Click here to download this release in PDF format.LCT lists on the International OTCQX
3 June, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY) today announced that it has listed its American Depositary Receipts (“ADRs”) on the International OTCQX and began trading Monday, June 2nd in the United States.
Click here to download this release in PDF format.Encapsulation technology presented to international conference in Florida
May 12, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) ) today announced that the Company has been invited to deliver a presentation on its unique encapsulation technology at the International Particles 2008 conference being held in Orlando, Florida, USA from May 10th -12th.
Click here to download this release in PDF format.Channel Ten feature LCT technology
8 May, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY) today announced that Australian television Channel Ten News will feature the Company’s world first islet cell treatment being developed for insulin dependent diabetes on its news segment between 5.00pm - 6.00pm this evening.
Click here to download this release in PDF format.OTCQX listing planned to further open exposure to US investors
8 May, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY) today announced it has applied to list its American Depository Receipt (ADR) program on the International OTCQX to increase the Company’s exposure to U.S. investors.
Click here to download this release in PDF format.LCT showcases proprietary nanotech
2 April, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY) today announced that Dr. Paul Tan, LCT CEO and Dr. Anil K Anal, LCT Material Scientist, presented data at a session on nanotechnology at the NZBio 2008 Conference in Auckland, New Zealand.
Click here to download this release in PDF format.LCT announces Positive 6 month trial
interim results
31 March, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY) today announced new positive 6 month interim results from the Phase I/IIa clinical trial of DiabeCell® for the treatment of type 1 diabetes at the International Diabetes Federation (IDF) Congress in Wellington, New Zealand and the NZBio Conference in Auckland, New Zealand.
Click here to download this release in PDF format.Living Cell Technologies and US- Based
Barbara Davis Center to collaborate on
Diabetes Clinical Trial Program
February 27, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that the Company has signed a term sheet with the Barbara Davis Center for Childhood Diabetes (BDC) to establish a diabetes clinical trial program in Denver, Colorado.
Click here to download this release in PDF format.Living Cell Technologies to Present Positive Preliminary Clinical Results at the International Diabetes Federation Congress
February 13, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that the Company's positive preliminary clinical results will be presented at the upcoming 7th International Diabetes Federation (IDF) Western Pacific Region Congress.
Click here to download this release in PDF format.Diabetes Trial Supported By US-Based Diabetes Foundation
February 12, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that the US based Children with Diabetes Foundation (CWDF), has offered its support in raising funds for LCT’s DiabeCell® clinical trials for people with type 1 diabetes. The foundation has established a fund which allows supporters of diabetes research to contribute tax deductible donations towards the trials.
Click here to download this release in PDF format.Living Cell Technologies Announces Conversion by Noteholders
January 25 , 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that its convertible noteholders have agreed to convert all the convertible notes issued by LCT on June 29, 2006, into ordinary shares of LCT.
Click here to download this release in PDF format.Living Cell Technologies Has the Funds to Capatilise on the Opportunities of 2008 – Australian Investor Article
January 2008 - The Australian Investor - 2007 was an exciting year for Living Cell Technologies, with the commencement of its clinical trials for its diabetes product in Russia. The preliminary results of this trial have been very encouraging and should provide a solid foundation for the Company moving forward in 2008.
Click here to download this article in PDF format.Living Cell Technologies to Receive US$6.0M through Exercise of Option
January 9, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that Palmert Members Limited (a British Virgin Island company) will purchase 24,150,408 ordinary shares of LCT at A$0.29 per share for an aggregate purchase price of US$6.0 million. Palmert will make this investment through exercising an option that was granted to NaviGroup Management Limited and assigned to Palmert by NaviGroup. The option, which expires on January 24, 2008 was exercised on December 20, 2007 and allows the holder to purchase up to US$6.0 million of LCT’s ordinary shares at 80% of the 30-day average closing bid price per ordinary share of the Company. The issue of these shares will occur at an exchange rate of US$0.8567 per AU$1.00 and is subject to certain shareholder approvals.
Click here to download this release in PDF format.Living Cell Technologies Appoints
New US-Based Director
January 8, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) - today announced the appointment of Dr. Robert Caspari of Boulder, Colorado to LCT’s Board of Directors as a Non Executive Director.
Click here to download this release in PDF format.Search our site
DiabeCell®
Natural neo-natal porcine islets encapsulated in an alginate gel and transplanted for the treatment of insulin-dependent diabetes.
More InformationNeurotrophinCell
A choroid plexus cell product with the potential to treat neurological diseases such as Huntington’s disease and stroke.
More InformationFac8Cell
A liver cell product aimed at producing factor 8, a blood clotting agent absent or defective in people suffering haemophilia.
More InformationEncapsulation Technology
LCT’s technology platform involves the implantation of healthy living cells to replace, repair or regenerate diseased or damaged organs.
More Information